Attention-Deficit Hyperactivity Disorder (ADHD) patients in New Zealand are set to benefit from a significant change in prescribing rules, effective February 1, 2026. This update expands the range of healthcare professionals who can assess, diagnose, and initiate treatment for ADHD, aiming to improve access and timeliness of care across the country. Previously, only pediatricians and psychiatrists could recommend ADHD medications, and general practitioners (GPs) and nurse practitioners could prescribe only after a diagnosis and initial prescription. Now, vocationally registered specialist GPs and nurse practitioners can start stimulant medications for adults aged 18 and over who have been diagnosed with ADHD. This change is part of a broader effort to build the specialist workforce and pathways needed to support safe, thorough assessments. While not every GP will take up this new responsibility, and services won't be available everywhere immediately, more pathways will be open for those seeking ADHD treatment. However, it's important to note that an ADHD assessment is complex and time-consuming, typically taking one to two hours and spanning multiple appointments. The cost of such assessments can vary depending on the type of service, local funding arrangements, and the time taken for assessment and follow-up. The new rules also allow GPs and nurse practitioners to prescribe publicly funded stimulant medications for ADHD, including methylphenidate, dexamfetamine, and lisdexamfetamine. However, global shortages of these medications due to high demand and limited manufacturing capacity are ongoing, and Pharmac is actively managing supply and exploring alternative brands and treatments to support increased demand. This change in prescribing rules is a significant step forward in making ADHD treatment more accessible and timely for patients across New Zealand, but it also highlights the ongoing challenges in ensuring a consistent supply of necessary medications.
